Login to Your Account



Raptiva Preliminary Data Poor In Psoriatic Arthritis Phase II

By Kim Coghill


Tuesday, March 23, 2004
Poor preliminary Phase II results of Raptiva in psoriatic arthritis patients caused slight dips in Genentech Inc. and XOMA Ltd.'s value. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription